Astarte Medical is the only precision medicine company using software and predictive analytics to improve outcomes in the first 1000 days.
Astarte Medical is the only precision medicine company using software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants. NICUtrition® by Astarte Medical supports feeding protocols, practice and decision-making in the neonatal ICU with a suite of digital tools and diagnostics designed to standardize feeding, optimize nutrition and quantify gut health. Core to Astarte Medical is its comprehensive and proprietary dataset that integrates feeding protocols, microbial profiles and clinical information. Its NICUtrition® suite of products provides actionable information in real time to hospitals and clinical teams, enabling them to standardize care protocols, and customize treatment plans by quantifying preterm infant gut health. Never is gut health more important than in the first 1,000 days of life as this is the most critical period of growth and brain development. In the future, Astarte Medical plans to develop precision care solutions that will improve prenatal and early infant outcomes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 22, 2021 | Series A | $7.60M | 1 | — | — | Detail |
Mar 7, 2019 | Series A | $5M | 1 | — | — | Detail |
May 16, 2018 | Seed | $250K | 1 | StartUp PHL | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
StartUp PHL | Yes | Seed |
Leatherneck Ventures | — | Series A |
Keiretsu Forum Mid Atlantic | — | Series A |